To support the above finding, a total of 45 GBM cases were assessed for MCT1, MCT4 and chaperone CD147 expressions, as well as for different glycolytic metabolism-related proteins, GLUT-1, HKII, CAIX and HIF-1α in normoxic regions (vascularized regions, distant from necrotic areas) and hypoxic regions (peri-necrotic areas). The gene discussed is SLC2A1; the disease is glioblastoma.